NASDAQ:CELC Celcuity Q2 2023 Earnings Report $10.80 -0.24 (-2.17%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$10.80 0.00 (0.00%) As of 04/25/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Celcuity EPS ResultsActual EPS-$0.66Consensus EPS -$0.67Beat/MissBeat by +$0.01One Year Ago EPSN/ACelcuity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACelcuity Announcement DetailsQuarterQ2 2023Date8/10/2023TimeN/AConference Call DateThursday, August 10, 2023Conference Call Time4:30PM ETUpcoming EarningsCelcuity's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Celcuity Q2 2023 Earnings Call TranscriptProvided by QuartrAugust 10, 2023 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 10th August, 2023. I would now like to turn the conference over to Robert Uhl, ICR Westwicke. Operator00:00:29Please go ahead. Speaker 100:00:32Thank you, operator, and good afternoon to everyone on the Thank you for joining us to review Celcuity's Q2 2023 financial results and business update. Earlier today, Celcuity released financial results for the Q2 ending June 30, 2023. The press release can be found on the Investors section of the company website. Joining me on the call today are Brian Sullivan, Cellcuity's Chief Executive Officer and Co Founder Vicki Hahn, Chief Financial Officer as well as Igor Gorbachevsky, Chief Medical Officer, who will be available during Q and A. Before we begin, I would like to remind listeners that our comments today will include some forward looking statements. Speaker 100:01:15These statements involve a number of risks and uncertainties, Which are outlined in today's press release and in our reports and filings with the SEC. Actual events All results may differ materially from those projected in the forward looking statements. Such forward looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non GAAP financial measures. These non GAAP measures are used by management to make strategic decisions, forecast future results and evaluate the company's current performance. Speaker 100:01:54Management believes the presentation of these non GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non GAAP financial measures to GAAP measures in today's press release. And with that, I would now like to turn the call over to Brian Sullivan, CEO of Cellcuity. Please go ahead. Speaker 200:02:19Thank you, Robert, and good afternoon to everyone joining us on today's call. Our top priority this quarter was continuing to HR positive HER2 negative advanced breast cancer, whose disease progressed while receiving a CDK4six inhibitor. A fantastic job of coordinating with regulatory authorities and individual sites to ensure our sites can begin recruiting patients as quickly as possible. They're relentlessly focused on keeping us on track to report the primary analysis for the PI3 ks non mutated patient subgroup in the second half of twenty twenty four the primary analysis for the PIK3CA mutated patient subgroup in the first half of twenty twenty five. This is consistent with our previously discussed expectations. Speaker 200:03:24We are seeking to improve outcomes for a patient population that receives limited benefit from current second line standard of care therapies. We estimate that this initial potential target population represents over 100,000 breast cancer patients globally on an annual basis. Current standard of care for these patients includes endocrine therapies such as fulvestrant and regimens that combine fulvestrant with an mTOR specific or PI3K alpha specific targeted therapy. These therapies offer only modest progression free survival periods and in the case of the approved PI3K alpha inhibitor, a very challenging safety profile. The significant unmet need for these breast cancer patients has led to development and subsequent investigation of a significant number of new therapies aimed at these patients. Speaker 200:04:11An oral SERD Median PFS for these 2 new therapies range from 3.8 to 5.5 months in our patient population. While the availability of new drug alternatives for patients As always good news, based on the results reported for these drugs, the unmet need for these patients will still remain. As we've discussed previously, there is a general consensus amongst leading breast cancer researchers that HR positive HER2 negative breast cancer involves the estrogen CDK4six and PI3KM4 pathways, each of which can cross activate the other. To most effectively treat this disease, We believe data from our Phase 1b study strongly suggests that simultaneous inhibition of these three pathways is required to optimize outcomes for these patients. And to date, randomized studies have consistently shown that partial inhibition of the PI3K mTOR pathway With drugs that only target a single component of this pathway, such as ones that target PI3K alpha, AKT or mTORC1 can provide only modest antitumor effects when patients have progressed on prior CDK4six treatment. Speaker 200:05:25Thus, we believe gatapalisib's Highly differentiated mechanism of action as an equipotent pan PI3K mTOR inhibitor is uniquely suited to most effectively address this unmet need, especially since gatapilisib has demonstrated activity independent of the presence of PIK3CA or ESR1 mutations in a patient's tumor. Our confidence that Gadasilis can play an important role in improving outcomes for women with HR positive HER2 negative advanced breast cancer was reinforced with the updated PFS data we reported at the ESMO Breast Cancer Commerce in May for first line patients from our Phase 1b study. Treatment naive patients with HR positive, HER2 negative advanced breast cancer treated with getasilisib, palbociclib and leprozol obtained a median progression free survival period of 48.6 months and 79% reported an objective response. Outcomes were comparable for patients with and without PIK3CA mutations, highlighting the rationale for comprehensive as opposed to selective Inhibition of the PI3K mTOR pathway. These results compare very favorably to the median PFS of 24.5 months and the 55% objective response rate reported in the PALOMA-three study for palociclib poflextrozole. Speaker 200:06:40We believe the data suggests getasolucid has the potential to eventually become a first line treatment option. Last year, we began evaluating and prioritizing new potential indications for getatilisib. We have set Previous trials for other PI3K and mTOR inhibitors and characterized the activity of gataplicib and other PI3KAKT mTOR inhibitors in different hormonally driven tumor types. Our initial results from non clinical studies in prostate cancer were presented at ASCO GU in February and in gynecological cancers at AACR in April. In each of these studies, get us a list of exhibited superior activity relative to all of the other PI3KAKT mTOR inhibitors evaluated. Speaker 200:07:20Thus, based on the review of prior clinical studies with PI3K, AKT and M4 inhibitors and our assessment of the relative advantage Gadasilisib's mechanism of action provides, we believe there is a significant opportunity for us to develop Gadasilisib in these additional tumor types over time. We expect to provide you with an update on our pipeline development strategy by the end of Q3. Now I'd like to shift our discussion to the diagnostic side of our business centers on Celsigna, our 3rd generation diagnostics platform. Our FACT 1 and FACT 2 trials are ongoing and enrolling patients with early stage HR positive HER2 negative breast cancer whose HER2 pathway is hyperactive as detected with our cell signaling test. We continue to expect to announce interim results from these studies in the first half of twenty twenty four. Speaker 200:08:08With that, I'll turn the call now over to Vicki Hahn to review our financial results. Speaker 300:08:14Thank you, Brian, and good afternoon to everyone. I'll provide a brief overview of our Q2 20 23 financial results. The 2nd quarter net loss was $14,600,000 or $0.66 loss per share compared to net loss of $10,000,000 or $0.67 loss per share for the Q2 2022. Because these quarterly net losses include significant non cash items including stock based compensation and interest expense, We also include in our press release non GAAP adjusted net loss for the quarter ending June 30, 2023. Our non GAAP adjusted net loss for the Q2 of 2023 was $12,800,000 or $0.58 Loss per share compared to non GAAP adjusted net loss for the Q2 of 2022 of $8,300,000 or $0.55 per share. Speaker 300:09:10Research and development expenses were $13,700,000 for the Q2 of 2023 compared to $8,400,000 for the Q2 of 2022. The approximately $5,400,000 increase During the Q2 of 2023, primarily resulted from cost supporting activities related to VICTORIA 1 Pivotal trial. We expect this expense to increase over the next two quarters consistent with the increase between Q2 and Q1 of 2023, again, primarily due to activities associated with Victoria 1. At that point, we expect expenses to remain roughly flat in 2024. General and administrative expenses were $1,300,000 for the Q2 of 2023 compared to $1,200,000 for the Q2 of 2022. Speaker 300:10:14Net cash used in operating activities for the Q2 of 2023 was $9,700,000 compared to $11,300,000 for the Q2 of 2022. This was a result of non GAAP adjusted net loss of approximately $12,800,000 offset by working capital changes of approximately $1,400,000 and changes in cash received from interest income related to maturities of $200,000 of cash, cash equivalents and short term investments compared to $168,600,000 at December 31, 2022. With that, I will now hand the call back to Brian. Speaker 200:11:04Thank you, Vicki. Operator, we're ready to take Operator00:11:21Your first question comes from the line of Maury Raycroft from Jefferies. Your line is now open. Speaker 400:11:28Hi. Thanks for taking my questions. I was just going to ask For the Phase 3, if there's any additional perspective you can share on how enrollment is going based on types of patients, potentially How it relates to wild type versus mutant patients and also geographic regions? Speaker 200:11:48So we're enrolling patients Consistently in all the regions. And some regions as expected will be more active than others, but we're not breaking that out Yes. And just at this point in time, but so far activities are proceeding as we expected. The site activations have gone well. The startups have gone well and the sites are engaged. Speaker 400:12:15Got it. Okay. And you mentioned that you're recruiting at nearly 200 sites in 20 countries. Are you going to open additional sites? Or are you satisfied with the current number of sites open enrollment rate, I guess any additional perspective there? Speaker 200:12:29We have some additional sites in the pipeline. And so in some ways they act as backup because not every Right. It does exactly what you'd like. And so we will over in effect activate we'll activate more than 200 sites to anticipate that some of these sites might not be as productive as we'd like. Some of these sites might not be as productive as we'd like. Speaker 400:12:50Got it. Okay. And one more question and then I'll hop back in the queue. I think you said in the past, there could be data this year supporting the 3 week on and 1 week off dosing schedule, which allows for the immune system holiday. When and in what forum should we expect to see data from that? Speaker 200:13:09Well, I think What we said was that we would have some data animal data that would show immune system activity We think it's consistent with what occurs during the 1 week off dose period With a 3 week on, 1 week off schedule. And we expect to cover that when we provide an update on our overall Pipeline, our R and D Day, so to speak, which will happen, we think, before the end of this quarter. Speaker 400:13:43Got it. Okay. Thanks for taking my questions. Speaker 200:13:46You're welcome. Operator00:13:49Your next question comes from the line of Maurice Peter from Cowen. Your line is now open. Speaker 500:13:54Great. Thanks for taking my question. My first question is on the VICTORIA-one trial. So my understanding is that Arm A is the key triplet arm in the study, which you plan to compare to arm C. I'm just curious does the success or failure of arm B really matter here? Speaker 200:14:12So RMB is intended to sort of 2 purposes. 1 is to potentially support Registration of GETTR plus fulvestrant. And that analysis B versus C is powered Independently and is going to be tested as a primary analysis. The second is that it helps Demonstrate the contribution of gatetilisib and allows analysis of the contribution of palaciclib. And so you will see or you want to see some form of arithmetic Difference between those three arms, but they don't statistically for purposes of supporting an A versus C comparison need to be significant. Speaker 500:15:02Great. And my second question also on VICTORIA trial. Do you have a sense of the dropout rate at this 1, maybe even on a blinded basis altogether? Speaker 200:15:14We don't. I mean, we have Again, this early in the study you get there's 2 factors, right? There's progression and then there's dropout due to Factors other than progression. We made assumptions in the trial that are probably pretty consistent with assumptions other companies made. And there's nothing that we've seen to date that would suggest There's anything different than what our assumptions were in terms of that would help inform A projection of primary analysis. Speaker 500:15:47Great. Thanks for taking my question. Speaker 200:15:50You're welcome. Operator00:15:53Your next question comes from the line of Gil Blum from Needham and Company. Your line is now open. Speaker 600:15:59Hello, everyone and good afternoon, Brian. Speaker 500:16:02Hi, Joe. Speaker 600:16:03So maybe a quick one on You mentioned a couple of agents that have had data recently. Assuming those are potentially approved at some point, could that Change the therapeutic landscape for getadulisibs combos? Thank you. Speaker 200:16:21Well, thanks for the question. We don't think so, because the benefit that's being reported isn't substantially better than what's Currently available in the case of the AKT inhibitor that reported data in this patient population. If you're doing a cross trial comparison at least, it appears that it's not it's comparable. The data suggests maybe not as good as the PSVT alpha inhibitor that's available. It has a better safety profile. Speaker 200:16:55So I'm sure the argument will be made that it can offer comparable anti tumor control with less toxicity. But it may be a legitimate and good alternative for patients in light of the current standard of care, but we don't think it necessarily Changes or raises the threshold of outcome for patients receiving these therapies. Gil, we can't hear you if you're still you're asking another question. Speaker 600:17:35Thank you, Brian. Speaker 200:17:36That was Speaker 600:17:37my only question. Speaker 200:17:38Okay. Thanks. Operator00:17:47Your next question comes from the line of Alex Nowak from Craig Hallum Capital Group. Your line is now open. Speaker 600:17:54Hi, good afternoon, everyone. This is Albert Hu on for Alex. So I have a question regarding And with the enrollment ramping and with you guys looking at other cancer indications, what additional investments And some talent and resources do you need to plan for? Speaker 200:18:15Sure. So we We closed the pipe transaction late last year that raised $100,000,000 and The intention of that pipe was to fund the VICTORIA-one study through data readout as well as to fund An early phase study in another tumor type. And the cost of an early phase study is relative certainly relatively very modest relative to a Phase 3 study And very modest in the scheme of things. And so the guidance we've provided about our cash runway has been through the end of 2025 and we're still confident that that's where we'll end up. Speaker 600:18:59Got you. Thank you. And as enrollment creeps higher, what sort of recruitment protocols Changes have you made or have you stuck to the same? Speaker 200:19:10I'm sorry, did you say recruitment Pro call? Protocols. Speaker 500:19:14Yes. Speaker 200:19:14Protocol. So no, the activity that we've started the study with and continuing and the overall approach To ensure patients are identified as early as possible, That's the site the trial's visibility at the site that patients are identified well in advance. That's been part of our strategy from day 1 and that's what we're sticking with and it's proven effective. We try to work as best we can with each of the sites to prescreen candidates or patients who are currently receiving CDK4six and those could be candidates for our study. We asked them to quantify that, so they actually we know that They've gone to their charts and identified patients. Speaker 200:20:06And then we try to monitor that to see if those numbers are changing. And that just helps us get a sense of the flow as well as whether or not the site is engaged. Each of our sites I get to visit every 2 weeks from a clinical research associate to monitor activities in this study, but also to assess Whether the study site is engaged overall and The recruitment activities are if everything is proceeding as should be. And so we feel like we have a very good footprint In the site, we're in regular contact. We separately establish contact and routine calls with the principal investigators at each of the sites. Speaker 200:20:57And so far, again, that's if you were to talk to People in this area, the engagement of the principal investigator plays a very, very significant role in how well the study Accrues at that site as well as the engagement of the study coordinator, who typically reports Either directly to the PI or to an organization. And so having those 2 individuals engaged It's critical and so those are among other things the people we try to pay a lot of attention To and keep track of and ensure that to the extent that if questions or things come up that we're able to respond as quickly as possible. Speaker 600:21:42Got you. And one last question here. So I believe you mentioned this briefly, but just to reiterate in the sites that Are live. What is the cadence of enrollment? And is it still tracking along well with your expectations? Operator00:21:58Sure. Speaker 200:22:01Each site is different. Some sites are community sites, some sites are very large And some sites just are typically better at keeping track of patients and therefore getting them in the queue for screening to be considered to be evaluated as a potential candidate. And so each site will Yes. You'll have a distribution of results across the number of sites that you have. And it's not quite the eightytwenty rule, but you always have your A it's like anything in life, right? Speaker 200:22:38You'll have your A accounts, your B accounts and your C accounts. And you manage accordingly. And so we've To be frank, we're very pleased with the general level of activity at all the sites. So, so far so good. Speaker 600:22:57Thank you. That's all my questions. Operator00:23:03There are no further questions at this time. I will now turn the call over to Brian Sullivan, Chief Executive Officer. Please go ahead, sir. Speaker 200:23:11Well, thank you. We appreciate your Attending the call. Appreciate the questions and look forward to updating you in the future. Goodbye. Operator00:23:22Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallCelcuity Q2 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Celcuity Earnings HeadlinesHedge Fund Managers Are Aggressively Buying Biotech Stocks Despite Trump Hinting at Pharma TariffsApril 9, 2025 | msn.comCelcuity (CELC) Receives a Buy from Stifel NicolausApril 2, 2025 | markets.businessinsider.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 27, 2025 | Porter & Company (Ad)Earnings call transcript: Celcuity Q4 2024 reveals wider lossesApril 2, 2025 | uk.investing.comCelcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comCelcuity To Present at Upcoming Needham and Stifel Investor ConferencesApril 1, 2025 | globenewswire.comSee More Celcuity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celcuity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celcuity and other key companies, straight to your email. Email Address About CelcuityCelcuity (NASDAQ:CELC), a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.View Celcuity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 10th August, 2023. I would now like to turn the conference over to Robert Uhl, ICR Westwicke. Operator00:00:29Please go ahead. Speaker 100:00:32Thank you, operator, and good afternoon to everyone on the Thank you for joining us to review Celcuity's Q2 2023 financial results and business update. Earlier today, Celcuity released financial results for the Q2 ending June 30, 2023. The press release can be found on the Investors section of the company website. Joining me on the call today are Brian Sullivan, Cellcuity's Chief Executive Officer and Co Founder Vicki Hahn, Chief Financial Officer as well as Igor Gorbachevsky, Chief Medical Officer, who will be available during Q and A. Before we begin, I would like to remind listeners that our comments today will include some forward looking statements. Speaker 100:01:15These statements involve a number of risks and uncertainties, Which are outlined in today's press release and in our reports and filings with the SEC. Actual events All results may differ materially from those projected in the forward looking statements. Such forward looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non GAAP financial measures. These non GAAP measures are used by management to make strategic decisions, forecast future results and evaluate the company's current performance. Speaker 100:01:54Management believes the presentation of these non GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non GAAP financial measures to GAAP measures in today's press release. And with that, I would now like to turn the call over to Brian Sullivan, CEO of Cellcuity. Please go ahead. Speaker 200:02:19Thank you, Robert, and good afternoon to everyone joining us on today's call. Our top priority this quarter was continuing to HR positive HER2 negative advanced breast cancer, whose disease progressed while receiving a CDK4six inhibitor. A fantastic job of coordinating with regulatory authorities and individual sites to ensure our sites can begin recruiting patients as quickly as possible. They're relentlessly focused on keeping us on track to report the primary analysis for the PI3 ks non mutated patient subgroup in the second half of twenty twenty four the primary analysis for the PIK3CA mutated patient subgroup in the first half of twenty twenty five. This is consistent with our previously discussed expectations. Speaker 200:03:24We are seeking to improve outcomes for a patient population that receives limited benefit from current second line standard of care therapies. We estimate that this initial potential target population represents over 100,000 breast cancer patients globally on an annual basis. Current standard of care for these patients includes endocrine therapies such as fulvestrant and regimens that combine fulvestrant with an mTOR specific or PI3K alpha specific targeted therapy. These therapies offer only modest progression free survival periods and in the case of the approved PI3K alpha inhibitor, a very challenging safety profile. The significant unmet need for these breast cancer patients has led to development and subsequent investigation of a significant number of new therapies aimed at these patients. Speaker 200:04:11An oral SERD Median PFS for these 2 new therapies range from 3.8 to 5.5 months in our patient population. While the availability of new drug alternatives for patients As always good news, based on the results reported for these drugs, the unmet need for these patients will still remain. As we've discussed previously, there is a general consensus amongst leading breast cancer researchers that HR positive HER2 negative breast cancer involves the estrogen CDK4six and PI3KM4 pathways, each of which can cross activate the other. To most effectively treat this disease, We believe data from our Phase 1b study strongly suggests that simultaneous inhibition of these three pathways is required to optimize outcomes for these patients. And to date, randomized studies have consistently shown that partial inhibition of the PI3K mTOR pathway With drugs that only target a single component of this pathway, such as ones that target PI3K alpha, AKT or mTORC1 can provide only modest antitumor effects when patients have progressed on prior CDK4six treatment. Speaker 200:05:25Thus, we believe gatapalisib's Highly differentiated mechanism of action as an equipotent pan PI3K mTOR inhibitor is uniquely suited to most effectively address this unmet need, especially since gatapilisib has demonstrated activity independent of the presence of PIK3CA or ESR1 mutations in a patient's tumor. Our confidence that Gadasilis can play an important role in improving outcomes for women with HR positive HER2 negative advanced breast cancer was reinforced with the updated PFS data we reported at the ESMO Breast Cancer Commerce in May for first line patients from our Phase 1b study. Treatment naive patients with HR positive, HER2 negative advanced breast cancer treated with getasilisib, palbociclib and leprozol obtained a median progression free survival period of 48.6 months and 79% reported an objective response. Outcomes were comparable for patients with and without PIK3CA mutations, highlighting the rationale for comprehensive as opposed to selective Inhibition of the PI3K mTOR pathway. These results compare very favorably to the median PFS of 24.5 months and the 55% objective response rate reported in the PALOMA-three study for palociclib poflextrozole. Speaker 200:06:40We believe the data suggests getasolucid has the potential to eventually become a first line treatment option. Last year, we began evaluating and prioritizing new potential indications for getatilisib. We have set Previous trials for other PI3K and mTOR inhibitors and characterized the activity of gataplicib and other PI3KAKT mTOR inhibitors in different hormonally driven tumor types. Our initial results from non clinical studies in prostate cancer were presented at ASCO GU in February and in gynecological cancers at AACR in April. In each of these studies, get us a list of exhibited superior activity relative to all of the other PI3KAKT mTOR inhibitors evaluated. Speaker 200:07:20Thus, based on the review of prior clinical studies with PI3K, AKT and M4 inhibitors and our assessment of the relative advantage Gadasilisib's mechanism of action provides, we believe there is a significant opportunity for us to develop Gadasilisib in these additional tumor types over time. We expect to provide you with an update on our pipeline development strategy by the end of Q3. Now I'd like to shift our discussion to the diagnostic side of our business centers on Celsigna, our 3rd generation diagnostics platform. Our FACT 1 and FACT 2 trials are ongoing and enrolling patients with early stage HR positive HER2 negative breast cancer whose HER2 pathway is hyperactive as detected with our cell signaling test. We continue to expect to announce interim results from these studies in the first half of twenty twenty four. Speaker 200:08:08With that, I'll turn the call now over to Vicki Hahn to review our financial results. Speaker 300:08:14Thank you, Brian, and good afternoon to everyone. I'll provide a brief overview of our Q2 20 23 financial results. The 2nd quarter net loss was $14,600,000 or $0.66 loss per share compared to net loss of $10,000,000 or $0.67 loss per share for the Q2 2022. Because these quarterly net losses include significant non cash items including stock based compensation and interest expense, We also include in our press release non GAAP adjusted net loss for the quarter ending June 30, 2023. Our non GAAP adjusted net loss for the Q2 of 2023 was $12,800,000 or $0.58 Loss per share compared to non GAAP adjusted net loss for the Q2 of 2022 of $8,300,000 or $0.55 per share. Speaker 300:09:10Research and development expenses were $13,700,000 for the Q2 of 2023 compared to $8,400,000 for the Q2 of 2022. The approximately $5,400,000 increase During the Q2 of 2023, primarily resulted from cost supporting activities related to VICTORIA 1 Pivotal trial. We expect this expense to increase over the next two quarters consistent with the increase between Q2 and Q1 of 2023, again, primarily due to activities associated with Victoria 1. At that point, we expect expenses to remain roughly flat in 2024. General and administrative expenses were $1,300,000 for the Q2 of 2023 compared to $1,200,000 for the Q2 of 2022. Speaker 300:10:14Net cash used in operating activities for the Q2 of 2023 was $9,700,000 compared to $11,300,000 for the Q2 of 2022. This was a result of non GAAP adjusted net loss of approximately $12,800,000 offset by working capital changes of approximately $1,400,000 and changes in cash received from interest income related to maturities of $200,000 of cash, cash equivalents and short term investments compared to $168,600,000 at December 31, 2022. With that, I will now hand the call back to Brian. Speaker 200:11:04Thank you, Vicki. Operator, we're ready to take Operator00:11:21Your first question comes from the line of Maury Raycroft from Jefferies. Your line is now open. Speaker 400:11:28Hi. Thanks for taking my questions. I was just going to ask For the Phase 3, if there's any additional perspective you can share on how enrollment is going based on types of patients, potentially How it relates to wild type versus mutant patients and also geographic regions? Speaker 200:11:48So we're enrolling patients Consistently in all the regions. And some regions as expected will be more active than others, but we're not breaking that out Yes. And just at this point in time, but so far activities are proceeding as we expected. The site activations have gone well. The startups have gone well and the sites are engaged. Speaker 400:12:15Got it. Okay. And you mentioned that you're recruiting at nearly 200 sites in 20 countries. Are you going to open additional sites? Or are you satisfied with the current number of sites open enrollment rate, I guess any additional perspective there? Speaker 200:12:29We have some additional sites in the pipeline. And so in some ways they act as backup because not every Right. It does exactly what you'd like. And so we will over in effect activate we'll activate more than 200 sites to anticipate that some of these sites might not be as productive as we'd like. Some of these sites might not be as productive as we'd like. Speaker 400:12:50Got it. Okay. And one more question and then I'll hop back in the queue. I think you said in the past, there could be data this year supporting the 3 week on and 1 week off dosing schedule, which allows for the immune system holiday. When and in what forum should we expect to see data from that? Speaker 200:13:09Well, I think What we said was that we would have some data animal data that would show immune system activity We think it's consistent with what occurs during the 1 week off dose period With a 3 week on, 1 week off schedule. And we expect to cover that when we provide an update on our overall Pipeline, our R and D Day, so to speak, which will happen, we think, before the end of this quarter. Speaker 400:13:43Got it. Okay. Thanks for taking my questions. Speaker 200:13:46You're welcome. Operator00:13:49Your next question comes from the line of Maurice Peter from Cowen. Your line is now open. Speaker 500:13:54Great. Thanks for taking my question. My first question is on the VICTORIA-one trial. So my understanding is that Arm A is the key triplet arm in the study, which you plan to compare to arm C. I'm just curious does the success or failure of arm B really matter here? Speaker 200:14:12So RMB is intended to sort of 2 purposes. 1 is to potentially support Registration of GETTR plus fulvestrant. And that analysis B versus C is powered Independently and is going to be tested as a primary analysis. The second is that it helps Demonstrate the contribution of gatetilisib and allows analysis of the contribution of palaciclib. And so you will see or you want to see some form of arithmetic Difference between those three arms, but they don't statistically for purposes of supporting an A versus C comparison need to be significant. Speaker 500:15:02Great. And my second question also on VICTORIA trial. Do you have a sense of the dropout rate at this 1, maybe even on a blinded basis altogether? Speaker 200:15:14We don't. I mean, we have Again, this early in the study you get there's 2 factors, right? There's progression and then there's dropout due to Factors other than progression. We made assumptions in the trial that are probably pretty consistent with assumptions other companies made. And there's nothing that we've seen to date that would suggest There's anything different than what our assumptions were in terms of that would help inform A projection of primary analysis. Speaker 500:15:47Great. Thanks for taking my question. Speaker 200:15:50You're welcome. Operator00:15:53Your next question comes from the line of Gil Blum from Needham and Company. Your line is now open. Speaker 600:15:59Hello, everyone and good afternoon, Brian. Speaker 500:16:02Hi, Joe. Speaker 600:16:03So maybe a quick one on You mentioned a couple of agents that have had data recently. Assuming those are potentially approved at some point, could that Change the therapeutic landscape for getadulisibs combos? Thank you. Speaker 200:16:21Well, thanks for the question. We don't think so, because the benefit that's being reported isn't substantially better than what's Currently available in the case of the AKT inhibitor that reported data in this patient population. If you're doing a cross trial comparison at least, it appears that it's not it's comparable. The data suggests maybe not as good as the PSVT alpha inhibitor that's available. It has a better safety profile. Speaker 200:16:55So I'm sure the argument will be made that it can offer comparable anti tumor control with less toxicity. But it may be a legitimate and good alternative for patients in light of the current standard of care, but we don't think it necessarily Changes or raises the threshold of outcome for patients receiving these therapies. Gil, we can't hear you if you're still you're asking another question. Speaker 600:17:35Thank you, Brian. Speaker 200:17:36That was Speaker 600:17:37my only question. Speaker 200:17:38Okay. Thanks. Operator00:17:47Your next question comes from the line of Alex Nowak from Craig Hallum Capital Group. Your line is now open. Speaker 600:17:54Hi, good afternoon, everyone. This is Albert Hu on for Alex. So I have a question regarding And with the enrollment ramping and with you guys looking at other cancer indications, what additional investments And some talent and resources do you need to plan for? Speaker 200:18:15Sure. So we We closed the pipe transaction late last year that raised $100,000,000 and The intention of that pipe was to fund the VICTORIA-one study through data readout as well as to fund An early phase study in another tumor type. And the cost of an early phase study is relative certainly relatively very modest relative to a Phase 3 study And very modest in the scheme of things. And so the guidance we've provided about our cash runway has been through the end of 2025 and we're still confident that that's where we'll end up. Speaker 600:18:59Got you. Thank you. And as enrollment creeps higher, what sort of recruitment protocols Changes have you made or have you stuck to the same? Speaker 200:19:10I'm sorry, did you say recruitment Pro call? Protocols. Speaker 500:19:14Yes. Speaker 200:19:14Protocol. So no, the activity that we've started the study with and continuing and the overall approach To ensure patients are identified as early as possible, That's the site the trial's visibility at the site that patients are identified well in advance. That's been part of our strategy from day 1 and that's what we're sticking with and it's proven effective. We try to work as best we can with each of the sites to prescreen candidates or patients who are currently receiving CDK4six and those could be candidates for our study. We asked them to quantify that, so they actually we know that They've gone to their charts and identified patients. Speaker 200:20:06And then we try to monitor that to see if those numbers are changing. And that just helps us get a sense of the flow as well as whether or not the site is engaged. Each of our sites I get to visit every 2 weeks from a clinical research associate to monitor activities in this study, but also to assess Whether the study site is engaged overall and The recruitment activities are if everything is proceeding as should be. And so we feel like we have a very good footprint In the site, we're in regular contact. We separately establish contact and routine calls with the principal investigators at each of the sites. Speaker 200:20:57And so far, again, that's if you were to talk to People in this area, the engagement of the principal investigator plays a very, very significant role in how well the study Accrues at that site as well as the engagement of the study coordinator, who typically reports Either directly to the PI or to an organization. And so having those 2 individuals engaged It's critical and so those are among other things the people we try to pay a lot of attention To and keep track of and ensure that to the extent that if questions or things come up that we're able to respond as quickly as possible. Speaker 600:21:42Got you. And one last question here. So I believe you mentioned this briefly, but just to reiterate in the sites that Are live. What is the cadence of enrollment? And is it still tracking along well with your expectations? Operator00:21:58Sure. Speaker 200:22:01Each site is different. Some sites are community sites, some sites are very large And some sites just are typically better at keeping track of patients and therefore getting them in the queue for screening to be considered to be evaluated as a potential candidate. And so each site will Yes. You'll have a distribution of results across the number of sites that you have. And it's not quite the eightytwenty rule, but you always have your A it's like anything in life, right? Speaker 200:22:38You'll have your A accounts, your B accounts and your C accounts. And you manage accordingly. And so we've To be frank, we're very pleased with the general level of activity at all the sites. So, so far so good. Speaker 600:22:57Thank you. That's all my questions. Operator00:23:03There are no further questions at this time. I will now turn the call over to Brian Sullivan, Chief Executive Officer. Please go ahead, sir. Speaker 200:23:11Well, thank you. We appreciate your Attending the call. Appreciate the questions and look forward to updating you in the future. Goodbye. Operator00:23:22Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.Read morePowered by